

xStAx-VHLL biochemical

xStAx-VHLL

CATALOG #
AAA227125


PRODUCT SYNONYMS

xStAx-VHLL; xStAx-VHLL biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
PLK4-IN-3, CAS 1247001-86-0



Structure
PLK4-IN-3, CAS 1247001-86-0

ADDITIONAL INFORMATION

Related Product Information for xStAx-VHLL biochemical	Selective peptide-based beta-catenin Degradator. Comprises a beta-catenin-targeted stapled peptide, xStAx, linked to a VHL-binding peptide. Reduces beta-catenin levels in HEK293T cells and colorectal cancer cell lines. Selectively degrades beta-catenin over other Wnt signaling pathway components. Inhibits tumor growth in APCmin/+ mice, with constitutively active Wnt signaling, and reduces survival of patient-derived colorectal cancer cell organoids.
References	1. Peter Brent Sampson, et al. KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME. Patent. WO2011123946A1.

NCBI AND UNIPROT INFORMATION

Molecular Weight	431.23
------------------	--------

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.